<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>KLONOPIN- clonazepam tablet </strong><br>Genentech, Inc.<br></p></div>
<h1>KLONOPIN<span class="Sup">®</span> TABLETS <br>(clonazepam)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">CIV</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Klonopin, a benzodiazepine, is available as scored tablets with a K-shaped perforation containing 0.5 mg of clonazepam and unscored tablets with a K-shaped perforation containing 1 mg or 2 mg of clonazepam. Each tablet also contains lactose, magnesium stearate, microcrystalline cellulose and corn starch, with the following colorants: 0.5 mg—FD&amp;C Yellow No. 6 Lake; 1 mg—FD&amp;C Blue No. 1 Lake and FD&amp;C Blue No. 2 Lake.</p>
<p>Chemically, clonazepam is 5-(2-chlorophenyl)-1,3-dihydro-7-nitro-2<span class="Italics">H</span>-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has a molecular weight of 315.72 and the following structural formula:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=542f22e8-dad2-47a8-93b6-30936715d73b&amp;name=klonopin-01.jpg"></div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="CP"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43681-6">
<a name="section-3.1"></a><p></p>
<h2>Pharmacodynamics</h2>
<p class="First">The precise mechanism by which clonazepam exerts its antiseizure and antipanic effects is unknown, although it is believed to be related to its ability to enhance the activity of gamma aminobutyric acid (GABA), the major inhibitory neurotransmitter in the central nervous system. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> produced in rodents by pentylenetetrazol or, to a lesser extent, electrical stimulation are antagonized, as are <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> produced by photic stimulation in susceptible baboons. A taming effect in aggressive primates, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> and hypnosis are also produced. In humans, clonazepam is capable of suppressing the spike and wave discharge in absence <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> (<span class="product-label-link" type="condition" conceptid="4194232" conceptname="Absence seizure">petit mal</span>) and decreasing the frequency, amplitude, duration and spread of discharge in minor motor <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-3.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">Clonazepam is rapidly and completely absorbed after oral administration. The absolute bioavailability of clonazepam is about 90%. Maximum plasma concentrations of clonazepam are reached within 1 to 4 hours after oral administration. Clonazepam is approximately 85% bound to plasma proteins. Clonazepam is highly metabolized, with less than 2% unchanged clonazepam being excreted in the urine. Biotransformation occurs mainly by reduction of the 7-nitro group to the 4-amino derivative. This derivative can be acetylated, hydroxylated and glucuronidated. Cytochrome P-450 including CYP3A, may play an important role in clonazepam reduction and oxidation. The elimination half-life of clonazepam is typically 30 to 40 hours. Clonazepam pharmacokinetics are dose-independent throughout the dosing range. There is no evidence that clonazepam induces its own metabolism or that of other drugs in humans.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.1"></a><p></p>
<h3>Pharmacokinetics in Demographic Subpopulations and in Disease States</h3>
<p class="First">Controlled studies examining the influence of gender and age on clonazepam pharmacokinetics have not been conducted, nor have the effects of renal or liver disease on clonazepam pharmacokinetics been studied. Because clonazepam undergoes hepatic metabolism, it is possible that liver disease will impair clonazepam elimination. Thus, caution should be exercised when administering clonazepam to these patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="CT"></a><a name="section-3.3"></a><p></p>
<h2>Clinical Trials</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">Panic Disorder</span></h3>
<p class="First">The effectiveness of Klonopin in the treatment of <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">panic disorder</span> was demonstrated in two double-blind, placebo-controlled studies of adult outpatients who had a primary diagnosis of <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">panic disorder</span> (DSM-IIIR) with or without <span class="product-label-link" type="condition" conceptid="4321835" conceptname="Agoraphobia">agoraphobia</span>. In these studies, Klonopin was shown to be significantly more effective than placebo in treating <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">panic disorder</span> on change from baseline in <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attack</span> frequency, the Clinician's Global Impression Severity of Illness Score and the Clinician's Global Impression Improvement Score.</p>
<p>Study 1 was a 9-week, fixed-dose study involving Klonopin doses of 0.5, 1, 2, 3 or 4 mg/day or placebo. This study was conducted in four phases: a 1-week placebo lead-in, a 3-week upward titration, a 6-week fixed dose and a 7-week discontinuance phase. A significant difference from placebo was observed consistently only for the 1 mg/day group. The difference between the 1 mg dose group and placebo in reduction from baseline in the number of full <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span> was approximately 1 <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attack</span> per week. At endpoint, 74% of patients receiving clonazepam 1 mg/day were free of full <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span>, compared to 56% of placebo-treated patients.</p>
<p>Study 2 was a 6-week, flexible-dose study involving Klonopin in a dose range of 0.5 to 4 mg/day or placebo. This study was conducted in three phases: a 1-week placebo lead-in, a 6-week optimal-dose and a 6-week discontinuance phase. The mean clonazepam dose during the optimal dosing period was 2.3 mg/day. The difference between Klonopin and placebo in reduction from baseline in the number of full <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span> was approximately 1 <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attack</span> per week. At endpoint, 62% of patients receiving clonazepam were free of full <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span>, compared to 37% of placebo-treated patients.</p>
<p>Subgroup analyses did not indicate that there were any differences in treatment outcomes as a function of race or gender.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="INDICATIONS"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> Disorders</h2>
<p class="First">Klonopin is useful alone or as an adjunct in the treatment of the Lennox-Gastaut syndrome (<span class="product-label-link" type="condition" conceptid="4194232" conceptname="Absence seizure">petit mal</span> variant), akinetic and myoclonic <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. In patients with absence <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> (<span class="product-label-link" type="condition" conceptid="4194232" conceptname="Absence seizure">petit mal</span>) who have failed to respond to succinimides, Klonopin may be useful.</p>
<p>In some studies, up to 30% of patients have shown a loss of anticonvulsant activity, often within 3 months of administration. In some cases, dosage adjustment may reestablish efficacy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">Panic Disorder</span></h2>
<p class="First">Klonopin is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">panic disorder</span>, with or without <span class="product-label-link" type="condition" conceptid="4321835" conceptname="Agoraphobia">agoraphobia</span>, as defined in DSM-IV. <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">Panic disorder</span> is characterized by the occurrence of unexpected <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span> and associated concern about having additional attacks, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">worry</span> about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks.</p>
<p>The efficacy of Klonopin was established in two 6- to 9-week trials in <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">panic disorder</span> patients whose diagnoses corresponded to the DSM-IIIR category of <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">panic disorder</span> (see <a href="#CT">CLINICAL PHARMACOLOGY: Clinical Trials</a>).</p>
<p><span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">Panic disorder</span> (DSM-IV) is characterized by recurrent unexpected <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span>, ie, a discrete period of intense <span class="product-label-link" type="condition" conceptid="4029621" conceptname="Fear">fear</span> or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, pounding heart or accelerated heart rate; (2) <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>; (3) <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">trembling</span> or <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span>; (4) sensations of <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or smothering; (5) feeling of <span class="product-label-link" type="condition" conceptid="4096712" conceptname="Choking">choking</span>; (6) <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>; (7) <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal distress</span>; (8) feeling dizzy, unsteady, lightheaded or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>; (9) <span class="product-label-link" type="condition" conceptid="4233346" conceptname="Derealization">derealization</span> (feelings of unreality) or <span class="product-label-link" type="condition" conceptid="4085688" conceptname="Loss of identity">depersonalization</span> (being <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">detached</span> from oneself); (10) <span class="product-label-link" type="condition" conceptid="4029621" conceptname="Fear">fear</span> of losing control; (11) <span class="product-label-link" type="condition" conceptid="4029621" conceptname="Fear">fear</span> of dying; (12) <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span> (<span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> or <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling sensations</span>); (13) <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> or <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span>.</p>
<p>The effectiveness of Klonopin in long-term use, that is, for more than 9 weeks, has not been systematically studied in controlled clinical trials. The physician who elects to use Klonopin for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient (see <a href="#DA">DOSAGE AND ADMINISTRATION</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="CONTRAINDICATIONS"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Klonopin should not be used in patients with a history of sensitivity to benzodiazepines, nor in patients with clinical or biochemical evidence of significant liver disease. It may be used in patients with <span class="product-label-link" type="condition" conceptid="435262" conceptname="Primary open angle glaucoma">open angle glaucoma</span> who are receiving appropriate therapy but is contraindicated in acute narrow angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="WARNINGS"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2>Interference With Cognitive and Motor Performance</h2>
<p class="First">Since Klonopin produces <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>, patients receiving this drug should be cautioned against engaging in hazardous occupations requiring mental alertness, such as operating machinery or driving a motor vehicle. They should also be warned about the concomitant use of alcohol or other CNS-depressant drugs during Klonopin therapy (see <a href="#DI">PRECAUTIONS: Drug Interactions</a> and <a href="#Patients">Information for Patients</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal Behavior</span> and Ideation</h2>
<p class="First">Antiepileptic drugs (AEDs), including Klonopin, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.</p>
<p>Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span> or ideation among 27,863 AED-treated patients was 0.43% compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated. There were four <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>.</p>
<p>The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed.</p>
<p>The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5-100 years) in the clinical trials analyzed.</p>
<p><a href="#t1">Table 1</a> shows absolute and relative risk by indication for all evaluated AEDs.</p>
<a name="t1"></a><table width="75%">
<caption><span>Table 1 Risk by Indication for Antiepileptic Drugs in the Pooled Analysis</span></caption>
<col align="left" valign="top" width="15%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Indication</th>
<th class="Rrule" align="left">Placebo Patients with Events Per 1000 Patients</th>
<th class="Rrule" align="left">Drug Patients with Events Per 1000 Patients</th>
<th class="Rrule" align="left">Relative Risk: Incidence of Events in Drug Patients/Incidence in Placebo Patients</th>
<th class="Rrule" align="left">Risk Difference: Additional Drug Patients with Events per 1000 Patients</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></td>
<td class="Rrule" align="left">1.0</td>
<td class="Rrule" align="left">3.4</td>
<td class="Rrule" align="left">3.5</td>
<td class="Rrule" align="left">2.4</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Psychiatric</td>
<td class="Rrule" align="left">5.7</td>
<td class="Rrule" align="left">8.5</td>
<td class="Rrule" align="left">1.5</td>
<td class="Rrule" align="left">2.9</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Other</td>
<td class="Rrule" align="left">1.0</td>
<td class="Rrule" align="left">1.8</td>
<td class="Rrule" align="left">1.9</td>
<td class="Rrule" align="left">0.9</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Total</td>
<td class="Rrule" align="left">2.4</td>
<td class="Rrule" align="left">4.3</td>
<td class="Rrule" align="left">1.8</td>
<td class="Rrule" align="left">1.9</td>
</tr>
</tbody>
</table>
<p>The relative risk for suicidal thoughts or behavior was higher in clinical trials for <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> and psychiatric indications.</p>
<p>Anyone considering prescribing Klonopin or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.</p>
<p>Patients, their caregivers, and families should be informed that AEDs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="WPR"></a><a name="section-6.3"></a><p></p>
<h2>Pregnancy Risks</h2>
<p class="First">Data from several sources raise concerns about the use of Klonopin during pregnancy.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.3.1"></a><p></p>
<h3>Animal Findings</h3>
<p class="First">In three studies in which Klonopin was administered orally to pregnant rabbits at doses of 0.2, 1, 5 or 10 mg/kg/day (low dose approximately 0.2 times the maximum recommended human dose of 20 mg/day for <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorders and equivalent to the maximum dose of 4 mg/day for <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">panic disorder</span>, on a mg/m<span class="Sup">2</span> basis) during the period of organogenesis, a similar pattern of malformations (<span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>, open eyelid, fused sternebrae and <span class="product-label-link" type="condition" conceptid="134741" conceptname="Congenital anomaly of limb">limb defects</span>) was observed in a low, non-dose-related incidence in exposed litters from all dosage groups. Reductions in maternal <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> occurred at dosages of 5 mg/kg/day or greater and reduction in embryo-fetal growth occurred in one study at a dosage of 10 mg/kg/day. No adverse maternal or embryo-fetal effects were observed in mice and rats following administration during organogenesis of oral doses up to 15 mg/kg/day or 40 mg/kg/day, respectively (4 and 20 times the maximum recommended human dose of 20 mg/day for <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorders and 20 and 100 times the maximum dose of 4 mg/day for <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">panic disorder</span>, respectively, on a mg/m<span class="Sup">2</span> basis).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.3.2"></a><p></p>
<h3>General Concerns and Considerations About Anticonvulsants</h3>
<p class="First">Recent reports suggest an association between the use of anticonvulsant drugs by women with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> and an elevated incidence of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in children born to these women. Data are more extensive with respect to diphenylhydantoin and phenobarbital, but these are also the most commonly prescribed anticonvulsants; less systematic or anecdotal reports suggest a possible similar association with the use of all known anticonvulsant drugs.</p>
<p>In children of women treated with drugs for <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, reports suggesting an elevated incidence of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> cannot be regarded as adequate to prove a definite cause and effect relationship. There are intrinsic methodologic problems in obtaining adequate data on drug <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> in humans; the possibility also exists that other factors (eg, genetic factors or the epileptic condition itself) may be more important than drug therapy in leading to <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>. The great majority of mothers on anticonvulsant medication deliver normal infants. It is important to note that anticonvulsant drugs should not be discontinued in patients in whom the drug is administered to prevent <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> because of the strong possibility of precipitating <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">status epilepticus</span> with attendant <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span> and threat to life. In individual cases where the severity and frequency of the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorder are such that the removal of medication does not pose a serious threat to the patient, discontinuation of the drug may be considered prior to and during pregnancy; however, it cannot be said with any confidence that even mild <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> do not pose some hazards to the developing embryo or fetus.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.3.3"></a><p></p>
<h3>General Concerns About Benzodiazepines</h3>
<p class="First">An increased risk of congenital malformations associated with the use of benzodiazepine drugs has been suggested in several studies.</p>
<p>There may also be non-teratogenic risks associated with the use of benzodiazepines during pregnancy. There have been reports of neonatal <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">flaccidity</span>, respiratory and feeding difficulties, and <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span> in children born to mothers who have been receiving benzodiazepines late in pregnancy. In addition, children born to mothers receiving benzodiazepines late in pregnancy may be at some risk of experiencing withdrawal symptoms during the postnatal period.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.3.4"></a><p></p>
<h3>Advice Regarding the Use of Klonopin in Women of Childbearing Potential</h3>
<p class="First">In general, the use of Klonopin in women of childbearing potential, and more specifically during known pregnancy, should be considered only when the clinical situation warrants the risk to the fetus.</p>
<p>The specific considerations addressed above regarding the use of anticonvulsants for <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> in women of childbearing potential should be weighed in treating or counseling these women.</p>
<p>Because of experience with other members of the benzodiazepine class, Klonopin is assumed to be capable of causing an increased risk of congenital abnormalities when administered to a pregnant woman during the first trimester. Because use of these drugs is rarely a matter of urgency in the treatment of <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">panic disorder</span>, their use during the first trimester should almost always be avoided. The possibility that a woman of childbearing potential may be pregnant at the time of institution of therapy should be considered. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Patients should also be advised that if they become pregnant during therapy or intend to become pregnant, they should communicate with their physician about the desirability of discontinuing the drug.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.4"></a><p></p>
<h2>Withdrawal Symptoms</h2>
<p class="First">Withdrawal symptoms of the barbiturate type have occurred after the discontinuation of benzodiazepines (see <a href="#DAD">DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="PRECAUTIONS"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.1"></a><p></p>
<h3>Worsening of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></h3>
<p class="First">When used in patients in whom several different types of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorders coexist, Klonopin may increase the incidence or precipitate the onset of generalized tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic seizures</span> (<span class="product-label-link" type="condition" conceptid="374924" conceptname="Generalized convulsive epilepsy">grand mal</span>). This may require the addition of appropriate anticonvulsants or an increase in their dosages. The concomitant use of valproic acid and Klonopin may produce absence status.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.2"></a><p></p>
<h3>Laboratory Testing During Long-Term Therapy</h3>
<p class="First">Periodic blood counts and liver function tests are advisable during long-term therapy with Klonopin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.3"></a><p></p>
<h3>Risks of Abrupt Withdrawal</h3>
<p class="First">The abrupt withdrawal of Klonopin, particularly in those patients on long-term, high-dose therapy, may precipitate <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">status epilepticus</span>. Therefore, when discontinuing Klonopin, gradual withdrawal is essential. While Klonopin is being gradually withdrawn, the simultaneous substitution of another anticonvulsant may be indicated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.4"></a><p></p>
<h3>Caution in Renally Impaired Patients</h3>
<p class="First">Metabolites of Klonopin are excreted by the kidneys; to avoid their excess accumulation, caution should be exercised in the administration of the drug to patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.5"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">Hypersalivation</span></h3>
<p class="First">Klonopin may produce an increase in <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span>. This should be considered before giving the drug to patients who have difficulty handling secretions. Because of this and the possibility of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, Klonopin should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="4063381" conceptname="Chronic disease of respiratory system">chronic respiratory diseases</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="Patients"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">A Klonopin Medication Guide must be given to the patient each time Klonopin is dispensed, as required by law. Patients should be instructed to take Klonopin only as prescribed. Physicians are advised to discuss the following issues with patients for whom they prescribe Klonopin:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.1"></a><p></p>
<h3>Dose Changes</h3>
<p class="First">To assure the safe and effective use of benzodiazepines, patients should be informed that, since benzodiazepines may produce psychological and physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, it is advisable that they consult with their physician before either increasing the dose or abruptly discontinuing this drug.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.2"></a><p></p>
<h3>Interference With Cognitive and Motor Performance</h3>
<p class="First">Because benzodiazepines have the potential to impair judgment, thinking or motor skills, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that Klonopin therapy does not affect them adversely.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.3"></a><p></p>
<h3>Suicidal Thinking and Behavior</h3>
<p class="First">Patients, their caregivers, and families should be counseled that AEDs, including Klonopin, may increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.4"></a><p></p>
<h3>Pregnancy</h3>
<p class="First">Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during therapy with Klonopin (see <a href="#WPR">WARNINGS: Pregnancy Risks</a>). Patients should be encouraged to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry if they become pregnant. This registry is collecting information about the safety of antiepileptic drugs during pregnancy. To enroll, patients can call the toll free number 1-888-233-2334 (see <a href="#Pregnancy">PRECAUTIONS: Pregnancy</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.5"></a><p></p>
<h3>Nursing</h3>
<p class="First">Patients should be advised not to breastfeed an infant if they are taking Klonopin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.6"></a><p></p>
<h3>Concomitant Medication</h3>
<p class="First">Patients should be advised to inform their physicians if they are taking, or plan to take, any prescription or over-the-counter drugs, since there is a potential for interactions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.7"></a><p></p>
<h3>Alcohol</h3>
<p class="First">Patients should be advised to avoid alcohol while taking Klonopin.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="DI"></a><a name="section-7.3"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.1"></a><p></p>
<h3>Effect of Clonazepam on the Pharmacokinetics of Other Drugs</h3>
<p class="First">Clonazepam does not appear to alter the pharmacokinetics of phenytoin, carbamazepine or phenobarbital. The effect of clonazepam on the metabolism of other drugs has not been investigated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.2"></a><p></p>
<h3>Effect of Other Drugs on the Pharmacokinetics of Clonazepam</h3>
<p class="First">Literature reports suggest that ranitidine, an agent that decreases stomach acidity, does not greatly alter clonazepam pharmacokinetics.</p>
<p>In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the C<span class="Sub">max</span> of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.</p>
<p>Fluoxetine does not affect the pharmacokinetics of clonazepam. Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels. Although clinical studies have not been performed, based on the involvement of the cytochrome P-450 3A family in clonazepam metabolism, inhibitors of this enzyme system, notably oral antifungal agents, should be used cautiously in patients receiving clonazepam.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.3"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">Pharmacodynamic Interactions</span></h3>
<p class="First">The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Carcinogenicity studies have not been conducted with clonazepam.</p>
<p>The data currently available are not sufficient to determine the genotoxic potential of clonazepam.</p>
<p>In a two-generation fertility study in which clonazepam was given orally to rats at 10 and 100 mg/kg/day (low dose approximately 5 times and 24 times the maximum recommended human dose of 20 mg/day for <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorder and 4 mg/day for <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">panic disorder</span>, respectively, on a mg/m<span class="Sup">2</span> basis), there was a decrease in the number of pregnancies and in the number of offspring surviving until weaning.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="Pregnancy"></a><a name="section-7.5"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.5.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.5.1.1"></a><p></p>
<h4>Pregnancy Category D</h4>
<p class="First">(see <a href="#WPR">WARNINGS: Pregnancy Risks</a>).</p>
<p>To provide information regarding the effects of in utero exposure to Klonopin, physicians are advised to recommend that pregnant patients taking Klonopin enroll in the NAAED Pregnancy Registry. This can be done by calling the toll free number 1-888-233-2334, and must be done by patients themselves. Information on this registry can also be found at the website http://www.aedpregnancyregistry.org/.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-7.6"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">The effect of Klonopin on labor and delivery in humans has not been specifically studied; however, perinatal complications have been reported in children born to mothers who have been receiving benzodiazepines late in pregnancy, including findings suggestive of either excess benzodiazepine exposure or of withdrawal phenomena (see <a href="#WPR">WARNINGS: Pregnancy Risks</a>).</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Mothers receiving Klonopin should not breastfeed their infants.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.8"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Because of the possibility that adverse effects on physical or mental development could become apparent only after many years, a benefit-risk consideration of the long-term use of Klonopin is important in pediatric patients being treated for <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorder (see <a href="#INDICATIONS">INDICATIONS AND USAGE</a> and <a href="#DA">DOSAGE AND ADMINISTRATION</a>).</p>
<p>Safety and effectiveness in pediatric patients with <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">panic disorder</span> below the age of 18 have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="GU"></a><a name="section-7.9"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of Klonopin did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>Because clonazepam undergoes hepatic metabolism, it is possible that liver disease will impair clonazepam elimination. Metabolites of Klonopin are excreted by the kidneys; to avoid their excess accumulation, caution should be exercised in the administration of the drug to patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased hepatic and/or renal function, care should be taken in dose selection, and it may be useful to assess hepatic and/or renal function at the time of dose selection.</p>
<p>Sedating drugs may cause <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and over-sedation in the elderly; elderly patients generally should be started on low doses of Klonopin and observed closely.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="AR"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The adverse experiences for Klonopin are provided separately for patients with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorders and with <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">panic disorder</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> Disorders</h2>
<p class="First">The most frequently occurring side effects of Klonopin are referable to <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>. Experience in treatment of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> has shown that <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> has occurred in approximately 50% of patients and <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span> in approximately 30%. In some cases, these may diminish with time; behavior problems have been noted in approximately 25% of patients. Others, listed by system, are:</p>
<p><span class="Italics">Neurologic: </span><span class="product-label-link" type="condition" conceptid="4012867" conceptname="Rolling of eyes">Abnormal eye movements</span>, <span class="product-label-link" type="condition" conceptid="40481303" conceptname="Aphonia">aphonia</span>, choreiform movements, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, <span class="product-label-link" type="condition" conceptid="4046815" conceptname="Dysdiadochokinesis">dysdiadochokinesis</span>, "glassy-eyed" appearance, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4065756" conceptname="Hemiparesis">hemiparesis</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span></p>
<p><span class="Italics">Psychiatric: </span><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="434889" conceptname="Dissociative disorder">hysteria</span>, <span class="product-label-link" type="condition" conceptid="4237753" conceptname="Increased libido">increased libido</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> (the behavior effects are more likely to occur in patients with a history of psychiatric disturbances). The following paradoxical reactions have been observed: <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitability</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disturbances</span>, <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span> and <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">vivid dreams</span></p>
<p><span class="Italics">Respiratory:</span> Chest congestion, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, hypersecretion in upper respiratory passages</p>
<p><span class="Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span></p>
<p><span class="Italics">Dermatologic:</span> <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Hair loss</span>, <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, ankle and facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span></p>
<p><span class="Italics">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span>, <span class="product-label-link" type="condition" conceptid="44784165" conceptname="Coating of mucous membrane of tongue">coated tongue</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="440695" conceptname="Encopresis">encopresis</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4009488" conceptname="Sore gums">sore gums</span></p>
<p><span class="Italics">Genitourinary:</span> <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">Dysuria</span>, <span class="product-label-link" type="condition" conceptid="193874" conceptname="Nocturnal enuresis">enuresis</span>, <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span></p>
<p><span class="Italics">Musculoskeletal:</span> <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pains</span></p>
<p><span class="Italics">Miscellaneous:</span> <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span>, general deterioration, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> or gain</p>
<p><span class="Italics">Hematopoietic:</span> <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span></p>
<p><span class="Italics">Hepatic:</span> <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span>, transient elevations of serum transaminases and alkaline phosphatase</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">Panic Disorder</span></h2>
<p class="First">Adverse events during exposure to Klonopin were obtained by spontaneous report and recorded by clinical investigators using terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse events without first grouping similar types of events into a smaller number of standardized event categories. In the tables and tabulations that follow, CIGY dictionary terminology has been used to classify reported adverse events, except in certain cases in which redundant terms were collapsed into more meaningful terms, as noted below.</p>
<p>The stated frequencies of adverse events represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse event of the type listed. An event was considered treatment-emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3"></a><p></p>
<h2>Adverse Findings Observed in Short-Term, Placebo-Controlled Trials</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.1"></a><p></p>
<h3>Adverse Events Associated With Discontinuation of Treatment</h3>
<p class="First">Overall, the incidence of discontinuation due to adverse events was 17% in Klonopin compared to 9% for placebo in the combined data of two 6- to 9-week trials. The most common events (≥1%) associated with discontinuation and a dropout rate twice or greater for Klonopin than that of placebo included the following:</p>
<table width="75%">
<caption><span>Table 2 Most Common Adverse Events (≥1%) Associated with Discontinuation of Treatment</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Adverse Event</th>
<th class="Rrule" align="center">Klonopin (N=574)</th>
<th class="Rrule" align="center">Placebo (N=294)</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td class="Rrule" align="center">7%</td>
<td class="Rrule" align="center">1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td class="Rrule" align="center">4%</td>
<td class="Rrule" align="center">1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">&lt;1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">0%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">Ataxia</span></td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">0%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Intellectual Ability Reduced</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">0%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.2"></a><p></p>
<h3>Adverse Events Occurring at an Incidence of 1% or More Among Klonopin-Treated Patients</h3>
<p class="First"><a href="#t3">Table 3</a> enumerates the incidence, rounded to the nearest percent, of treatment-emergent adverse events that occurred during acute therapy of <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">panic disorder</span> from a pool of two 6- to 9-week trials. Events reported in 1% or more of patients treated with Klonopin (doses ranging from 0.5 to 4 mg/day) and for which the incidence was greater than that in placebo-treated patients are included.</p>
<p>The prescriber should be aware that the figures in <a href="#t3">Table 3</a> cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses and investigators. The cited figures, however, do provide the prescribing physician with some basis for estimating the relative contribution of drug and nondrug factors to the side effect incidence in the population studied.</p>
<a name="t3"></a><table width="100%">
<caption><span>Table 3 Treatment-Emergent Adverse Event Incidence in 6- to 9-Week Placebo-Controlled Clinical Trials<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></span></caption>
<col align="left" valign="top" width="28%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<thead>
<tr class="First"><th class="Botrule Lrule Rrule" align="center" colspan="7">Clonazepam Maximum Daily Dose</th></tr>
<tr class="Last" valign="bottom">
<th class="Lrule" align="left">Adverse Event<br>by Body System</th>
<th class="Lrule Rrule" align="center">&lt;1mg<br>n=96<br>%</th>
<th align="center">1-&lt;2mg<br>n=129<br>%</th>
<th class="Lrule Rrule" align="center">2-&lt;3mg<br>n=113<br>%</th>
<th align="center">≥3mg<br>n=235<br>%</th>
<th class="Lrule Rrule" align="center">All Klonopin Groups<br>N=574<br>%</th>
<th class="Rrule" align="center">Placebo<br>N=294<br>%</th>
</tr>
</thead>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Events reported by at least 1% of patients treated with Klonopin and for which the incidence was greater than that for placebo.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Indicates that the p-value for the dose-trend test (Cochran-Mantel-Haenszel) for adverse event incidence was ≤0.10.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>Denominators for events in gender-specific systems are: n=240 (clonazepam), 102 (placebo) for male, and 334 (clonazepam), 192 (placebo) for female.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule" align="left">Central &amp; Peripheral Nervous System</td>
<td class="Lrule Rrule" align="center"></td>
<td align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</td>
<td class="Lrule Rrule" align="center">26</td>
<td align="center">35</td>
<td class="Lrule Rrule" align="center">50</td>
<td align="center">36</td>
<td class="Lrule Rrule" align="center">37</td>
<td class="Rrule" align="center">10</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Lrule Rrule" align="center">5</td>
<td align="center">5</td>
<td class="Lrule Rrule" align="center">12</td>
<td align="center">8</td>
<td class="Lrule Rrule" align="center">8</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">Coordination Abnormal</span><a href="#footnote-2" class="Sup">†</a>
</td>
<td class="Lrule Rrule" align="center">1</td>
<td align="center">2</td>
<td class="Lrule Rrule" align="center">7</td>
<td align="center">9</td>
<td class="Lrule Rrule" align="center">6</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">Ataxia</span><a href="#footnote-2" class="Sup">†</a>
</td>
<td class="Lrule Rrule" align="center">2</td>
<td align="center">1</td>
<td class="Lrule Rrule" align="center">8</td>
<td align="center">8</td>
<td class="Lrule Rrule" align="center">5</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">Dysarthria</span><a href="#footnote-2" class="Sup">†</a>
</td>
<td class="Lrule Rrule" align="center">0</td>
<td align="center">0</td>
<td class="Lrule Rrule" align="center">4</td>
<td align="center">3</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule" align="left">Psychiatric</td>
<td class="Lrule Rrule" align="center"></td>
<td align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td class="Lrule Rrule" align="center">7</td>
<td align="center">6</td>
<td class="Lrule Rrule" align="center">8</td>
<td align="center">8</td>
<td class="Lrule Rrule" align="center">7</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">Memory Disturbance</span></td>
<td class="Lrule Rrule" align="center">2</td>
<td align="center">5</td>
<td class="Lrule Rrule" align="center">2</td>
<td align="center">5</td>
<td class="Lrule Rrule" align="center">4</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></td>
<td class="Lrule Rrule" align="center">1</td>
<td align="center">4</td>
<td class="Lrule Rrule" align="center">3</td>
<td align="center">4</td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr>
<td class="Lrule" align="left">  Intellectual Ability Reduced</td>
<td class="Lrule Rrule" align="center">0</td>
<td align="center">2</td>
<td class="Lrule Rrule" align="center">4</td>
<td align="center">3</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">Emotional Lability</span></td>
<td class="Lrule Rrule" align="center">0</td>
<td align="center">1</td>
<td class="Lrule Rrule" align="center">2</td>
<td align="center">2</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="443262" conceptname="Lack or loss of sexual desire">Libido Decreased</span></td>
<td class="Lrule Rrule" align="center">0</td>
<td align="center">1</td>
<td class="Lrule Rrule" align="center">3</td>
<td align="center">1</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span></td>
<td class="Lrule Rrule" align="center">0</td>
<td align="center">2</td>
<td class="Lrule Rrule" align="center">2</td>
<td align="center">1</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule" align="left">Respiratory System</td>
<td class="Lrule Rrule" align="center"></td>
<td align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper Respiratory Tract Infection</span><a href="#footnote-2" class="Sup">†</a>
</td>
<td class="Lrule Rrule" align="center">10</td>
<td align="center">10</td>
<td class="Lrule Rrule" align="center">7</td>
<td align="center">6</td>
<td class="Lrule Rrule" align="center">8</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td class="Lrule Rrule" align="center">4</td>
<td align="center">2</td>
<td class="Lrule Rrule" align="center">8</td>
<td align="center">4</td>
<td class="Lrule Rrule" align="center">4</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></td>
<td class="Lrule Rrule" align="center">3</td>
<td align="center">2</td>
<td class="Lrule Rrule" align="center">4</td>
<td align="center">2</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Coughing</span></td>
<td class="Lrule Rrule" align="center">2</td>
<td align="center">2</td>
<td class="Lrule Rrule" align="center">4</td>
<td align="center">0</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></td>
<td class="Lrule Rrule" align="center">1</td>
<td align="center">1</td>
<td class="Lrule Rrule" align="center">3</td>
<td align="center">2</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span></td>
<td class="Lrule Rrule" align="center">1</td>
<td align="center">0</td>
<td class="Lrule Rrule" align="center">2</td>
<td align="center">2</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr>
<td class="Lrule" align="left">Gastrointestinal System</td>
<td class="Lrule Rrule" align="center"></td>
<td align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span><a href="#footnote-2" class="Sup">†</a>
</td>
<td class="Lrule Rrule" align="center">0</td>
<td align="center">1</td>
<td class="Lrule Rrule" align="center">5</td>
<td align="center">3</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Appetite Decreased</span></td>
<td class="Lrule Rrule" align="center">1</td>
<td align="center">1</td>
<td class="Lrule Rrule" align="center">0</td>
<td align="center">3</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span><a href="#footnote-2" class="Sup">†</a>
</td>
<td class="Lrule Rrule" align="center">2</td>
<td align="center">2</td>
<td class="Lrule Rrule" align="center">2</td>
<td align="center">0</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr>
<td class="Lrule" align="left">Body as a Whole</td>
<td class="Lrule Rrule" align="center"></td>
<td align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Lrule Rrule" align="center">9</td>
<td align="center">6</td>
<td class="Lrule Rrule" align="center">7</td>
<td align="center">7</td>
<td class="Lrule Rrule" align="center">7</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reaction</span></td>
<td class="Lrule Rrule" align="center">3</td>
<td align="center">1</td>
<td class="Lrule Rrule" align="center">4</td>
<td align="center">2</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr>
<td class="Lrule" align="left">Musculoskeletal</td>
<td class="Lrule Rrule" align="center"></td>
<td align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td class="Lrule Rrule" align="center">2</td>
<td align="center">1</td>
<td class="Lrule Rrule" align="center">4</td>
<td align="center">0</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr>
<td class="Lrule" align="left">Resistance Mechanism Disorders</td>
<td class="Lrule Rrule" align="center"></td>
<td align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span></td>
<td class="Lrule Rrule" align="center">3</td>
<td align="center">2</td>
<td class="Lrule Rrule" align="center">5</td>
<td align="center">5</td>
<td class="Lrule Rrule" align="center">4</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr>
<td class="Lrule" align="left">Urinary System</td>
<td class="Lrule Rrule" align="center"></td>
<td align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  Micturition Frequency</td>
<td class="Lrule Rrule" align="center">1</td>
<td align="center">2</td>
<td class="Lrule Rrule" align="center">2</td>
<td align="center">1</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span><a href="#footnote-2" class="Sup">†</a>
</td>
<td class="Lrule Rrule" align="center">0</td>
<td align="center">0</td>
<td class="Lrule Rrule" align="center">2</td>
<td align="center">2</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule" align="left">Vision Disorders</td>
<td class="Lrule Rrule" align="center"></td>
<td align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred Vision</span></td>
<td class="Lrule Rrule" align="center">1</td>
<td align="center">2</td>
<td class="Lrule Rrule" align="center">3</td>
<td align="center">0</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr>
<td class="Lrule" align="left">Reproductive Disorders<a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a>
</td>
<td class="Lrule Rrule" align="center"></td>
<td align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  Female</td>
<td class="Lrule Rrule" align="center"></td>
<td align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">Dysmenorrhea</span></td>
<td class="Lrule Rrule" align="center">0</td>
<td align="center">6</td>
<td class="Lrule Rrule" align="center">5</td>
<td align="center">2</td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">Colpitis</span></td>
<td class="Lrule Rrule" align="center">4</td>
<td align="center">0</td>
<td class="Lrule Rrule" align="center">2</td>
<td align="center">1</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr>
<td class="Lrule" align="left">  Male</td>
<td class="Lrule Rrule" align="center"></td>
<td align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4036117" conceptname="Late ejaculation">Ejaculation Delayed</span></td>
<td class="Lrule Rrule" align="center">0</td>
<td align="center">0</td>
<td class="Lrule Rrule" align="center">2</td>
<td align="center">2</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span></td>
<td class="Lrule Rrule" align="center">3</td>
<td align="center">0</td>
<td class="Lrule Rrule" align="center">2</td>
<td align="center">1</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.3"></a><p></p>
<h3>Commonly Observed Adverse Events</h3>
<table width="85%">
<caption><span>Table 4              Incidence of Most Commonly Observed Adverse Events<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a> in Acute Therapy in Pool of 6- to 9-Week Trials</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<thead><tr class="First Last">
<th class="Lrule" align="left">Adverse Event<br>(Genentech Preferred Term)</th>
<th class="Lrule Rrule" align="center">Clonazepam<br>(N=574)</th>
<th class="Rrule" align="center">Placebo<br>(N=294)</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>Treatment-emergent events for which the incidence in the clonazepam patients was ≥5% and at least twice that in the placebo patients.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td class="Lrule Rrule" align="center">37%</td>
<td class="Rrule" align="center">10%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td class="Lrule Rrule" align="center">7%</td>
<td class="Rrule" align="center">1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">Coordination Abnormal</span></td>
<td class="Lrule Rrule" align="center">6%</td>
<td class="Rrule" align="center">0%</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">Ataxia</span></td>
<td class="Lrule Rrule" align="center">5%</td>
<td class="Rrule" align="center">0%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.4"></a><p></p>
<h3>Treatment-Emergent <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">Depressive Symptoms</span></h3>
<p class="First">In the pool of two short-term placebo-controlled trials, adverse events classified under the preferred term "<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>" were reported in 7% of Klonopin-treated patients compared to 1% of placebo-treated patients, without any clear pattern of dose relatedness. In these same trials, adverse events classified under the preferred term "<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>" were reported as leading to discontinuation in 4% of Klonopin-treated patients compared to 1% of placebo-treated patients. While these findings are noteworthy, Hamilton <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> Rating Scale (HAM-D) data collected in these trials revealed a larger decline in HAM-D scores in the clonazepam group than the placebo group suggesting that clonazepam-treated patients were not experiencing a worsening or emergence of clinical <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.5"></a><p></p>
<h3>Other Adverse Events Observed During the Premarketing Evaluation of Klonopin in <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">Panic Disorder</span></h3>
<p class="First">Following is a list of modified CIGY terms that reflect treatment-emergent adverse events reported by patients treated with Klonopin at multiple doses during clinical trials. All reported events are included except those already listed in <a href="#t3">Table 3</a> or elsewhere in labeling, those events for which a drug cause was remote, those event terms which were so general as to be uninformative, and events reported only once and which did not have a substantial probability of being acutely life-threatening. It is important to emphasize that, although the events occurred during treatment with Klonopin, they were not necessarily caused by it.</p>
<p>Events are further categorized by body system and listed in order of decreasing frequency. These adverse events were reported infrequently, which is defined as occurring in 1/100 to 1/1000 patients.</p>
<p><span class="Italics">Body as a Whole: </span><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increase</span>, <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accident</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decrease</span>, <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">shivering</span>, <span class="product-label-link" type="condition" conceptid="4269361" conceptname="Friction burn">abrasions</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">ankle edema</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> foot, <span class="product-label-link" type="condition" conceptid="4177665" conceptname="Periorbital edema">edema periorbital</span>, injury, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation localized</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">hypotension postural</span></p>
<p><span class="Italics">Central and Peripheral <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="435140" conceptname="Toxic effect of alcohol">drunkenness</span>, feeling of <span class="product-label-link" type="condition" conceptid="193874" conceptname="Nocturnal enuresis">enuresis</span>, <span class="product-label-link" type="condition" conceptid="4154696" conceptname="Spastic paresis">paresis</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4010479" conceptname="Sensation of burning of skin">burning skin</span>, <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span>, head fullness, <span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">hoarseness</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="432941" conceptname="Disorder of tongue">tongue thick</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span></p>
<p><span class="Italics">Gastrointestinal System Disorders:</span> <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="437915" conceptname="Gastrointestinal mucositis">gastrointestinal inflammation</span>, <span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">stomach upset</span>, <span class="product-label-link" type="condition" conceptid="4099176" conceptname="Toothache">toothache</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">pyrosis</span>, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">saliva increased</span>, <span class="product-label-link" type="condition" conceptid="4122115" conceptname="Tooth disorder">tooth disorder</span>, bowel movements frequent, <span class="product-label-link" type="condition" conceptid="4147829" conceptname="Pain in pelvis">pain pelvic</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="194382" conceptname="External hemorrhoids">hemorrhoids</span></p>
<p><span class="Italics">Hearing and <span class="product-label-link" type="condition" conceptid="81303" conceptname="Labyrinthine disorder">Vestibular Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="4183452" conceptname="Otitis">otitis</span>, <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">earache</span>, <span class="product-label-link" type="condition" conceptid="30284" conceptname="Motion sickness">motion sickness</span></p>
<p><span class="Italics">Heart Rate and Rhythm Disorders:</span> <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span></p>
<p><span class="Italics">Metabolic and Nutritional Disorders:</span> <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span></p>
<p><span class="Italics">Musculoskeletal System Disorders:</span> <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> traumatic, <span class="product-label-link" type="condition" conceptid="30234" conceptname="Neck sprain">sprains</span> and <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> leg, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> nape, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span> muscle, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps leg</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">pain ankle</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> shoulder, <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">lumbago</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> feet, <span class="product-label-link" type="condition" conceptid="4168686" conceptname="Jaw pain">pain jaw</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">pain knee</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> knee</p>
<p><span class="Italics">Platelet, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> and <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">Clotting Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> dermal</p>
<p><span class="Italics">Psychiatric Disorders:</span> <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, organic <span class="product-label-link" type="condition" conceptid="4249261" conceptname="Disinhibition">disinhibition</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4085688" conceptname="Loss of identity">depersonalization</span>, <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">dreaming excessive</span>, libido loss, appetite increased, <span class="product-label-link" type="condition" conceptid="4237753" conceptname="Increased libido">libido increased</span>, reactions decreased, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive reaction</span>, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">apathy</span>, attention lack, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span>, feeling mad, <span class="product-label-link" type="condition" conceptid="4205415" conceptname="Hungry">hunger</span> abnormal, <span class="product-label-link" type="condition" conceptid="4238753" conceptname="Optical illusion">illusion</span>, <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span>, <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorder</span>, <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> ideation, <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span></p>
<p><span class="Italics">Reproductive Disorders, Female:</span> <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span>, <span class="product-label-link" type="condition" conceptid="196168" conceptname="Irregular periods">menstrual irregularity</span></p>
<p><span class="Italics">Reproductive Disorders, Male:</span> <span class="product-label-link" type="condition" conceptid="4088757" conceptname="Anejaculation">ejaculation decreased</span></p>
<p><span class="Italics">Resistance Mechanism Disorders:</span> <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">infection mycotic</span>, <span class="product-label-link" type="condition" conceptid="40493255" conceptname="Viral syndrome">infection viral</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> streptococcal, herpes simplex <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="437784" conceptname="Infectious mononucleosis">infectious mononucleosis</span>, <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory System Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing excessive</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic attack</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">nosebleed</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="78786" conceptname="Pleurisy">pleurisy</span></p>
<p><span class="Italics">Skin and Appendages Disorders:</span> <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> flare, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="4198562" conceptname="Xeroderma">xeroderma</span>, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">dermatitis contact</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, pustular reaction, skin <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span>, <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin disorder</span></p>
<p><span class="Italics">Special Senses Other, Disorders:</span> <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">taste loss</span></p>
<p><span class="Italics">Urinary System Disorders:</span> <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>, bladder dysfunction, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, urinary tract <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="4055281" conceptname="Urine color abnormal">urine discoloration</span></p>
<p><span class="Italics">Vascular (Extracardiac) Disorders:</span> <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis leg</span></p>
<p><span class="Italics">Vision Disorders:</span> <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbance</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, eye <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>, <span class="product-label-link" type="condition" conceptid="380403" conceptname="External hordeolum">styes</span>, <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">visual field defect</span>, <span class="product-label-link" type="condition" conceptid="4180937" conceptname="Xerophthalmia">xerophthalmia</span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="DAD"></a><a name="section-9"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34085-1">
<a name="section-9.1"></a><p></p>
<h2>Controlled Substance Class</h2>
<p class="First">Clonazepam is a Schedule IV controlled substance.</p>
</div>
<div class="Section" data-sectionCode="34087-7">
<a name="section-9.2"></a><p></p>
<h2>Physical and Psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<p class="First">Withdrawal symptoms, similar in character to those noted with barbiturates and alcohol (eg, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, behavioral disorder, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, abdominal and <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>) have occurred following abrupt discontinuance of clonazepam. The more severe withdrawal symptoms have usually been limited to those patients who received excessive doses over an extended period of time. Generally milder withdrawal symptoms (eg, <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span> and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>) have been reported following abrupt discontinuance of benzodiazepines taken continuously at therapeutic levels for several months. Consequently, after extended therapy, abrupt discontinuation should generally be avoided and a gradual dosage tapering schedule followed (see <a href="#DA">DOSAGE AND ADMINISTRATION</a>). Addiction-prone individuals (such as drug addicts or alcoholics) should be under careful surveillance when receiving clonazepam or other psychotropic agents because of the predisposition of such patients to <span class="product-label-link" type="condition" conceptid="4036424" conceptname="Drug tolerance">habituation</span> and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>.</p>
<p>Following the short-term treatment of patients with <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">panic disorder</span> in Studies 1 and 2 (see <a href="#CT">CLINICAL PHARMACOLOGY: Clinical Trials</a>), patients were gradually withdrawn during a 7-week downward-titration (discontinuance) period. Overall, the discontinuance period was associated with good tolerability and a very modest clinical deterioration, without evidence of a significant rebound phenomenon. However, there are not sufficient data from adequate and well-controlled long-term clonazepam studies in patients with <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">panic disorder</span> to accurately estimate the risks of withdrawal symptoms and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> that may be associated with such use.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2>Human Experience</h2>
<p class="First">Symptoms of clonazepam overdosage, like those produced by other CNS depressants, include <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> and <span class="product-label-link" type="condition" conceptid="4044603" conceptname="Hyporeflexia">diminished reflexes</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> Management</h2>
<p class="First">Treatment includes monitoring of respiration, pulse and blood pressure, general supportive measures and immediate gastric lavage. Intravenous fluids should be administered and an adequate airway maintained. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> may be combated by the use of levarterenol or metaraminol. Dialysis is of no known value.</p>
<p>Flumazenil, a specific benzodiazepine-receptor antagonist, is indicated for the complete or partial reversal of the sedative effects of benzodiazepines and may be used in situations when an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with a benzodiazepine is known or suspected. Prior to the administration of flumazenil, necessary measures should be instituted to secure airway, ventilation and intravenous access. Flumazenil is intended as an adjunct to, not as a substitute for, proper management of benzodiazepine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Patients treated with flumazenil should be monitored for resedation, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and other residual benzodiazepine effects for an appropriate period after treatment. <span class="Bold">The prescriber should be aware of a risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> in association with flumazenil treatment, particularly in long-term benzodiazepine users and in cyclic antidepressant <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</span> The complete flumazenil package insert, including CONTRAINDICATIONS, WARNINGS and PRECAUTIONS, should be consulted prior to use.</p>
<p><span class="Bold">Flumazenil is not indicated in patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> who have been treated with benzodiazepines. Antagonism of the benzodiazepine effect in such patients may provoke <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.</span></p>
<p>Serious sequelae are rare unless other drugs or alcohol have been taken concomitantly.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="DA"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Clonazepam is available as a tablet. The tablets should be administered with water by swallowing the tablet whole.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> Disorders</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1.1"></a><p></p>
<h3>Adults</h3>
<p class="First">The initial dose for adults with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorders should not exceed 1.5 mg/day divided into three doses. Dosage may be increased in increments of 0.5 to 1 mg every 3 days until <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> are adequately controlled or until side effects preclude any further increase. Maintenance dosage must be individualized for each patient depending upon response. Maximum recommended daily dose is 20 mg.</p>
<p>The use of multiple anticonvulsants may result in an increase of depressant adverse effects. This should be considered before adding Klonopin to an existing anticonvulsant regimen.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1.2"></a><p></p>
<h3>Pediatric Patients</h3>
<p class="First">Klonopin is administered orally. In order to minimize <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, the initial dose for infants and children (up to 10 years of age or 30 kg of body weight) should be between 0.01 and 0.03 mg/kg/day but not to exceed 0.05 mg/kg/day given in two or three divided doses. Dosage should be increased by no more than 0.25 to 0.5 mg every third day until a daily maintenance dose of 0.1 to 0.2 mg/kg of body weight has been reached, unless <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> are controlled or side effects preclude further increase. Whenever possible, the daily dose should be divided into three equal doses. If doses are not equally divided, the largest dose should be given before retiring.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1.3"></a><p></p>
<h3>Geriatric Patients</h3>
<p class="First">There is no clinical trial experience with Klonopin in <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorder patients 65 years of age and older. In general, elderly patients should be started on low doses of Klonopin and observed closely (see <a href="#GU">PRECAUTIONS: Geriatric Use</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">Panic Disorder</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1"></a><p></p>
<h3>Adults</h3>
<p class="First">The initial dose for adults with <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">panic disorder</span> is 0.25 mg bid. An increase to the target dose for most patients of 1 mg/day may be made after 3 days. The recommended dose of 1 mg/day is based on the results from a fixed dose study in which the optimal effect was seen at 1 mg/day. Higher doses of 2, 3 and 4 mg/day in that study were less effective than the 1 mg/day dose and were associated with more adverse effects. Nevertheless, it is possible that some individual patients may benefit from doses of up to a maximum dose of 4 mg/day, and in those instances, the dose may be increased in increments of 0.125 to 0.25 mg bid every 3 days until <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">panic disorder</span> is controlled or until side effects make further increases undesired. To reduce the inconvenience of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, administration of one dose at bedtime may be desirable.</p>
<p>Treatment should be discontinued gradually, with a decrease of 0.125 mg bid every 3 days, until the drug is completely withdrawn.</p>
<p>There is no body of evidence available to answer the question of how long the patient treated with clonazepam should remain on it. Therefore, the physician who elects to use Klonopin for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.2"></a><p></p>
<h3>Pediatric Patients</h3>
<p class="First">There is no clinical trial experience with Klonopin in <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">panic disorder</span> patients under 18 years of age.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.3"></a><p></p>
<h3>Geriatric Patients</h3>
<p class="First">There is no clinical trial experience with Klonopin in <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">panic disorder</span> patients 65 years of age and older. In general, elderly patients should be started on low doses of Klonopin and observed closely (see <a href="#GU">PRECAUTIONS: Geriatric Use</a>).</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="how"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Klonopin tablets are available as scored tablets with a K-shaped perforation—0.5 mg, orange (NDC 0004-0068-01); and unscored tablets with a K-shaped perforation—1 mg, blue (NDC 0004-0058-01); 2 mg, white (NDC 0004-0098-01)—bottles of 100.</p>
<p>Imprint on tablets:</p>
<table class="Noautorules" width="60%">
<col align="right" valign="top" width="10%">
<col align="center" valign="top" width="10%">
<col align="left" valign="top" width="30%">
<col align="left" valign="top" width="50%">
<tbody class="Headless">
<tr>
<td align="right">0.5 mg</td>
<td align="center">—</td>
<td align="left">1/2 KLONOPIN (front) <br>ROCHE (scored side)</td>
<td align="left"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=542f22e8-dad2-47a8-93b6-30936715d73b&amp;name=klonopin-02.jpg"></td>
</tr>
<tr>
<td align="right">1 mg</td>
<td align="center">—</td>
<td align="left">1 KLONOPIN (front) <br>ROCHE (reverse side)</td>
<td align="left"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=542f22e8-dad2-47a8-93b6-30936715d73b&amp;name=klonopin-03.jpg"></td>
</tr>
<tr>
<td align="right">2 mg</td>
<td align="center">—</td>
<td align="left">2 KLONOPIN (front) <br>ROCHE (reverse side)</td>
<td align="left"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=542f22e8-dad2-47a8-93b6-30936715d73b&amp;name=klonopin-04.jpg"></td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="section-12.1"></a><p></p>
<p class="First">Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13"></a><p></p>
<p class="First">Distributed by:</p>
<p><span class="Bold">Genentech USA, Inc.</span><br>A Member of the Roche Group <br> 1 DNA Way <br>South San Francisco, CA 94080-4990</p>
<p>Revised: December 2013</p>
<p>© 2013 Genentech, Inc. All rights reserved.</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="section-14"></a><p></p>
<h1>Medication Guide</h1>
<p class="First"><span class="Bold">KLONOPIN<span class="Sup">®</span> (KLON-oh-pin)<br>(clonazepam)<br>Tablets</span></p>
<p><span class="Bold">CIV</span></p>
<p>Read this Medication Guide before you start taking KLONOPIN and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment.</p>
<p>KLONOPIN can cause serious side effects. Because stopping KLONOPIN suddenly can also cause serious problems, do not stop taking KLONOPIN without talking to your healthcare provider first.</p>
<p><a name="mi"></a><span class="Bold">What is the most important information I should know about KLONOPIN?</span></p>
<p><span class="Bold">Do not stop taking KLONOPIN without first talking to your healthcare provider. </span>Stopping KLONOPIN suddenly can cause serious problems.</p>
<p><span class="Bold">KLONOPIN can cause serious side effects, including: </span></p>
<dl class="Unordered">
<dt class="Bold">1.</dt>
<dd>
<span class="Bold">KLONOPIN can slow your thinking and motor skills</span><ul>
<li>Do not drive, operate heavy machinery, or do other dangerous activities until you know how KLONOPIN affects you.</li>
<li>Do not drink alcohol or take other drugs that may make you <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span> or dizzy while taking KLONOPIN until you talk to your healthcare provider. When taken with alcohol or drugs that cause <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, KLONOPIN may make your <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> worse.</li>
</ul>
</dd>
<dt class="Bold">2.</dt>
<dd>
<span class="Bold">Like other antiepileptic drugs, KLONOPIN may cause suicidal thoughts or actions in a very small number of people, about 1 in 500.<br><br>Call a healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">worry</span> you: </span><ul class="Square">
<li>thoughts about <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> or dying</li>
<li>attempt to commit <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span></li>
<li>new or worse <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></li>
<li>new or worse <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span></li>
<li>feeling <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> or <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restless</span></li>
<li><span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span></li>
<li>trouble sleeping (<span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>)</li>
<li>new or worse <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span></li>
<li>acting aggressive, being angry, or violent</li>
<li>acting on dangerous impulses</li>
<li>an extreme increase in activity and talking (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>)</li>
<li>other unusual changes in behavior or mood</li>
</ul>
<br><span class="Bold">How can I watch for early symptoms of suicidal thoughts and actions? </span><ul>
<li>Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. </li>
<li>Keep all follow-up visits with your healthcare provider as scheduled.</li>
</ul>
<br>Call your healthcare provider between visits as needed, especially if you are worried about symptoms.<br><br>Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes.<br><br><span class="Bold">Do not stop KLONOPIN without first talking to a healthcare provider. </span><br><br>Stopping  KLONOPIN suddenly can cause serious problems. Stopping KLONOPIN suddenly can cause <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> that will not stop (<span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">status epilepticus</span>).</dd>
<dt class="Bold">3.</dt>
<dd>
<span class="Bold">KLONOPIN may harm your unborn or developing baby. </span><ul>
<li>If you take KLONOPIN during pregnancy, your baby is at risk for serious <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>. These defects can happen as early as in the first month of pregnancy, even before you know you are pregnant. <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">Birth defects</span> may occur even in children born to women who are not taking any medicines and do not have other risk factors.</li>
<li>Children born to mothers receiving benzodiazepine medications (including KLONOPIN) late in pregnancy may be at some risk of experiencing breathing problems, feeding problems, <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>, and withdrawal symptoms.</li>
<li>Tell your healthcare provider right away if you become pregnant while taking KLONOPIN. You and your healthcare provider should decide if you will take KLONOPIN while you are pregnant.</li>
<li>If you become pregnant while taking KLONOPIN, talk to your healthcare provider about registering with the North American Antiepileptic Drug Pregnancy Registry. You can register by calling 1-888-233-2334. The purpose of this registry is to collect information about the safety of antiepileptic drugs during pregnancy.</li>
<li>KLONOPIN can pass into breast milk. Talk to your healthcare provider about the best way to feed your baby if you take KLONOPIN. You and your healthcare provider should decide if you will take KLONOPIN or breast feed. You should not do both.</li>
</ul>
</dd>
<dt class="Bold">4.</dt>
<dd>
<span class="Bold">KLONOPIN can cause abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>.</span><ul class="Disc"><li>Do not stop taking KLONOPIN all of a sudden. Stopping KLONOPIN   suddenly can cause <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> that do not stop, hearing or seeing things   that are not there (<span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>), <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span>, and stomach and muscle   <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>.<ul class="Circle">
<li>Talk to your doctor about slowly stopping KLONOPIN to avoid getting sick with withdrawal symptoms.</li>
<li>Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> is not the same as <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug addiction</span>. Your healthcare provider can tell you more about the differences between physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug addiction</span>.</li>
</ul>
</li></ul>
</dd>
</dl>
<p><span class="Bold">KLONOPIN is a federally controlled substance (C-IV) because it can be abused or lead to <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>. Keep KLONOPIN in a safe place to prevent misuse and abuse. Selling or giving away KLONOPIN may harm others, and is against the law. Tell your doctor if you have ever abused or been dependent on alcohol, prescription medicines or street drugs.</span></p>
<p><span class="Bold">What is KLONOPIN?</span></p>
<p>KLONOPIN is a prescription medicine used alone or with other medicines to treat:</p>
<ul>
<li>certain types of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorders (<span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>)  in adults and children</li>
<li><span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">panic disorder</span> with or without <span class="product-label-link" type="condition" conceptid="4029621" conceptname="Fear">fear</span> of open spaces (<span class="product-label-link" type="condition" conceptid="4321835" conceptname="Agoraphobia">agoraphobia</span>) in adults</li>
</ul>
<p>It is not known if KLONOPIN is safe or effective in treating <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">panic disorder</span> in children younger than 18 years old.</p>
<p><span class="Bold">Who should not take KLONOPIN?</span></p>
<p>Do not take KLONOPIN if you:</p>
<ul>
<li>are allergic to benzodiazepines </li>
<li>have significant liver disease</li>
<li>have an eye disease called acute narrow angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span></li>
</ul>
<p><span class="Bold">Ask your healthcare provider if you are not sure if you have any of the problems listed above.</span></p>
<p><span class="Bold">What should I tell my healthcare provider before taking KLONOPIN?</span></p>
<p>Before you take KLONOPIN, tell your healthcare provider if you:</p>
<ul>
<li>have liver or kidney problems</li>
<li>have lung problems (respiratory disease)</li>
<li>have or have had <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, mood problems, or suicidal thoughts or behavior</li>
<li>have any other medical conditions</li>
</ul>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take,</span> including prescription and non-prescription medicines, vitamins, and herbal supplements. Taking KLONOPIN with certain other medicines can cause side effects or affect how well they work. Do not start or stop other medicines without talking to your healthcare provider.</p>
<p>Know the medicines you take. Keep a list of them and show it to your healthcare provider and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take KLONOPIN?</span></p>
<ul>
<li>Take KLONOPIN exactly as your healthcare provider tells you. KLONOPIN is available as a tablet.</li>
<li>Do not stop taking KLONOPIN without first talking to your healthcare provider. Stopping KLONOPIN suddenly can cause serious problems.</li>
<li>
<span class="Bold">KLONOPIN tablets</span> should be taken with water and swallowed whole.</li>
<li>If you take too much KLONOPIN, call your healthcare provider or local Poison Control Center right away.</li>
</ul>
<p><span class="Bold">What should I avoid while taking KLONOPIN?</span></p>
<ul>
<li> KLONOPIN can slow your thinking and motor skills. Do not drive, operate heavy machinery, or do other dangerous activities until you know how KLONOPIN affects you.</li>
<li>Do not drink alcohol or take other drugs that may make you <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span> or dizzy while taking KLONOPIN until you talk to your healthcare provider. When taken with alcohol or drugs that cause <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, KLONOPIN may make your <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> worse.</li>
</ul>
<p><span class="Bold">What are the possible side effects of KLONOPIN?</span></p>
<p><span class="Bold">See "<a href="#mi">What is the most important information I should know about KLONOPIN?</a>"</span></p>
<p>KLONOPIN can also make your <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> happen more often or make them worse. Call your healthcare provider right away if your <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> get worse while taking KLONOPIN.</p>
<p>The most common side effects of KLONOPIN include:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span></li>
<li>Problems with walking and coordination</li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></li>
<li><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></li>
<li>Problems with memory</li>
</ul>
<p>These are not all the possible side effects of KLONOPIN. For more information, ask your healthcare provider or pharmacist.</p>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store KLONOPIN?</span></p>
<ul class="Disc"><li>Store KLONOPIN between 59°F to 86°F (15°C to 30°C)</li></ul>
<p><span class="Bold">Keep KLONOPIN and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General Information about KLONOPIN</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use KLONOPIN for a condition for which it was not prescribed. Do not give KLONOPIN to other people, even if they have the same symptoms that you have. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about KLONOPIN. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about KLONOPIN that is written for health professionals.</p>
<p>For more information, go to www.gene.com/gene/products/information/klonopin or call 1-888-835-2555.</p>
<p><span class="Bold">What are the ingredients in KLONOPIN?</span></p>
<p>Active ingredient: clonazepam</p>
<p>Inactive ingredients:</p>
<ul class="Disc"><li>Tablets: 						<ul class="Circle">
<li>0.5 mg tablets contain lactose, magnesium stearate, microcrystalline cellulose, corn starch, FD&amp;C Yellow No. 6 Lake</li>
<li>1 mg tablets contain lactose, magnesium stearate, microcrystalline cellulose, corn starch, FD&amp;C Blue No. 1 Lake and FD&amp;C Blue No. 2 Lake</li>
<li>2 mg tablets contain lactose, magnesium stearate, microcrystalline cellulose, corn starch</li>
</ul>
</li></ul>
<p>Issued: December 2013</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p>Distributed by:</p>
<p><span class="Bold">Genentech USA, Inc.</span><br>A Member of the Roche Group<br>1 DNA Way<br>South San Francisco, CA 94080-4990</p>
<p>© 2013 Genentech, Inc. All rights reserved.</p>
<p>For additional copies of this Medication Guide, please call 1-877-436-3683 or visit www.gene.com/gene/products/information/klonopin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15"></a><p></p>
<p class="First">Representative sample of labeling (see <a href="#how">HOW SUPPLIED</a> section for complete listing):</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 0.5 mg Label</h1>
<p class="First">NDC 0004-0068-01</p>
<p><span class="Bold">Klonopin</span><span class="Sup">®</span><br>(clonazepam)</p>
<p><span class="Bold">CIV</span></p>
<p><span class="Bold">0.5 mg</span></p>
<p>Each tablet contains 0.5 mg clonazepam.</p>
<p><span class="Bold">ATTENTION PHARMACIST: Dispense the accompanying <br>Medication Guide to each patient. For additional <br>Medication Guides call 1-877-436-3683 or visit <br>www.gene.com/gene/products/information/klonopin.</span></p>
<p><span class="Bold">100 tablets<br>Rx only</span></p>
<p><span class="Bold">Genentech</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 0.5 mg Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=542f22e8-dad2-47a8-93b6-30936715d73b&amp;name=klonopin-05.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 1 mg Label</h1>
<p class="First">NDC 0004-0058-01</p>
<p><span class="Bold">Klonopin</span><span class="Sup">®</span><br>(clonazepam)</p>
<p><span class="Bold">CIV</span></p>
<p><span class="Bold">1 mg</span></p>
<p>Each tablet contains 1 mg clonazepam.</p>
<p><span class="Bold">ATTENTION PHARMACIST: Dispense the accompanying <br>Medication Guide to each patient. For additional <br>Medication Guides call 1-877-436-3683 or visit <br>www.gene.com/gene/products/information/klonopin.</span></p>
<p><span class="Bold">100 tablets<br>Rx only</span></p>
<p><span class="Bold">Genentech</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 1 mg Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=542f22e8-dad2-47a8-93b6-30936715d73b&amp;name=klonopin-06.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 2 mg Label</h1>
<p class="First">NDC 0004-0098-01</p>
<p><span class="Bold">Klonopin</span><span class="Sup">®</span><br>(clonazepam)</p>
<p><span class="Bold">CIV</span></p>
<p><span class="Bold">2 mg</span></p>
<p>Each tablet contains 2 mg clonazepam.</p>
<p><span class="Bold">ATTENTION PHARMACIST: Dispense the accompanying <br>Medication Guide to each patient. For additional <br>Medication Guides call 1-877-436-3683 or visit <br>www.gene.com/gene/products/information/klonopin.</span></p>
<p><span class="Bold">100 tablets<br>Rx only</span></p>
<p><span class="Bold">Genentech</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 2 mg Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=542f22e8-dad2-47a8-93b6-30936715d73b&amp;name=klonopin-07.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>KLONOPIN 		
					</strong><br><span class="contentTableReg">clonazepam tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0004-0068</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIV    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Clonazepam</strong> (Clonazepam) </td>
<td class="formItem">Clonazepam</td>
<td class="formItem">0.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>starch, corn</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Yellow No. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALUMINUM OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">1;2;KLONOPIN;ROCHE</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0004-0068-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA017533</td>
<td class="formItem">06/02/1975</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>KLONOPIN 		
					</strong><br><span class="contentTableReg">clonazepam tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0004-0058</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIV    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Clonazepam</strong> (Clonazepam) </td>
<td class="formItem">Clonazepam</td>
<td class="formItem">1 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>starch, corn</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Blue No. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALUMINUM OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Blue No. 2</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">1;KLONOPIN;ROCHE</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0004-0058-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA017533</td>
<td class="formItem">06/02/1975</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>KLONOPIN 		
					</strong><br><span class="contentTableReg">clonazepam tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0004-0098</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIV    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Clonazepam</strong> (Clonazepam) </td>
<td class="formItem">Clonazepam</td>
<td class="formItem">2 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>starch, corn</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">2;KLONOPIN;ROCHE</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0004-0098-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA017533</td>
<td class="formItem">06/02/1975</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Genentech, Inc.
							(080129000)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">DSM Nutritional Products AG</td>
<td class="formItem"></td>
<td class="formItem">482688756</td>
<td class="formItem">API MANUFACTURE(0004-0058, 0004-0068, 0004-0098), ANALYSIS(0004-0058, 0004-0068, 0004-0098)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Productos Roche S.A. de C.V.</td>
<td class="formItem"></td>
<td class="formItem">588441795</td>
<td class="formItem">MANUFACTURE(0004-0058, 0004-0068, 0004-0098), ANALYSIS(0004-0058, 0004-0068, 0004-0098), PACK(0004-0058, 0004-0068, 0004-0098), LABEL(0004-0058, 0004-0068, 0004-0098)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>6f0237c8-528e-4fd7-b05b-34801a6a3ed6</div>
<div>Set id: 542f22e8-dad2-47a8-93b6-30936715d73b</div>
<div>Version: 9</div>
<div>Effective Time: 20131212</div>
</div>
</div> <div class="DistributorName">Genentech, Inc.</div></p>
</body></html>
